# Per Samuelsson

> Per Samuelsson is a Series A investor at HealthCap (Stockholm) backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [HealthCap](https://shizune.co/investors/profile/healthcap)
- Location: Stockholm, Sweden
- Total investments: 3
- Last investment: Sep 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/samuelssonper
- X (Twitter): https://twitter.com/biotechps
- Website: https://x.com/biotechps

Per Samuelsson is a Series A investor at HealthCap in Stockholm focused on Medical and Health Care. Per Samuelsson is based out of Stockholm, Stockholms Lan and is the Partner of HealthCap. Per previously worked at ABB Aros Securites as a Director, Corporate Finance. Per Samuelsson attended the The Institute of Technology at Linköping University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Germany | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pretzel Therapeutics | Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinatingfeatures that make it unlike any other organelle in the body. | $72.5M | Series A | Sep 12, 2022 |  |
| Ariceum Therapeutics | Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers. | $26.8M | Series A | Jun 08, 2022 |  |
| Nucleonics | Nucleonics is a biotechnology company focused on RNA interference-based therapeutics. | $49.2M | Series B | Jun 02, 2004 |  |

3 of 3 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Mubadala Capital Ventures](https://shizune.co/investors/profile/mubadala-ventures) — VC Fund, 2 deals together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 1 deal together
- [Cambridge Innovation Capital](https://shizune.co/investors/profile/cambridge-innovation-capital) — VC Fund, 1 deal together
- [EIR Ventures](https://shizune.co/investors/profile/eir-ventures) — VC Fund, 1 deal together

## About HealthCap

VC Fund · Stockholm, Sweden

HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized provider of venture capital within life sciences Europe.

5 contacts available at HealthCap.

| Name | Title | Profile |
| --- | --- | --- |
| Bjorn Odlander | Founder and Partner | https://shizune.co/investors/profile/bjorn-odlander |
| Marten Steen | Partner | https://shizune.co/investors/profile/marten-steen |
| Per Samuelsson | Partner | https://shizune.co/investors/profile/per-samuelsson |
| Anki Forsberg | Partner | https://shizune.co/investors/profile/anki-forsberg |
| Carl Dalsgaard | Venture Partner | https://shizune.co/investors/profile/carl-johan-dalsgaard |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Per Samuelsson invest in?

Per Samuelsson invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Per Samuelsson last invest?

The most recent investment recorded for Per Samuelsson closed in Sep 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co